
|Articles|May 3, 2022
CATO SMS Unveils New Name; Allucent
Advertisement
CATO SMS unveiled its new name, Allucent, to emphasize the company's spotlight on serving the specialized needs of small and mid-sized biotech companies.
This move follows a three-year series of strategic acquisitions, most recently of clinical research provider, Pharm-Olam. Now, Allucent is a unified organization with more than 30 years of experience, built to support small and mid-sized biotech companies with achieving breakthrough science.
Read more about the rebranding
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale
2
From Participation to Understanding: Reframing Engagement in Clinical Trials
3
Beyond Compliance: NetraMark's Joseph Geraci, PhD, on Making AI-Driven Patient Subgroups Explainable
4
ACT Brief: Hidden RBQM Value, Rare Disease Patient Partnership, and Safety Perception in IBD
5




